NPC
ICPT

National Planning Corporation’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

National Planning Corporation’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-63,100
Closed -$3.66M – 655
2017
Q3 		$3.66M Buy
63,100
+10,905
+21% +$1.17M 0.31% 69
2017
Q2 		$6.38M Sell
52,195
-205
-0.4% -$23.7K 0.49% 42
2017
Q1 		$5.89M Sell
52,400
-320
-0.6% -$37.4K 0.45% 50
2016
Q4 		$5.67M Buy
52,720
+210
+0.4% +$25K 0.44% 47
2016
Q3 		$5.29M Buy
52,510
+1,675
+3% +$264K 0.42% 52
2016
Q2 		$8.67M Buy
50,835
+325
+0.6% +$47.4K 0.67% 26
2016
Q1 		$6.74M Buy
50,510
+24,305
+93% +$2.87M 0.59% 32
2015
Q4 		$2.58M Buy
26,205
+625
+2% +$106K 0.21% 106
2015
Q3 		$4.72M Buy
25,580
+225
+0.9% +$49.5K 0.43% 53
2015
Q2 		$6.01M Buy
25,355
+2,350
+10% +$626K 0.54% 35
2015
Q1 		$5.93M Buy
23,005
+22,880
+18,304% +$4.95M 0.53% 40
2014
Q4 		$19.7K Buy
+125
New +$23.1K ﹤0.01% 1731

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Planning Corporation's ICPT Position: Q4 2017 in Review

National Planning Corporation sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2017, closing a stake of 63,100 shares — an estimated $3.66M sold.

National Planning Corporation first reported a position in ICPT in Q4 2014 and held it in 12 quarters. The position peaked at $8.67M in Q2 2016. 168 funds tracked by Wall St. Rank hold ICPT as of Q4 2017.

  • National Planning Corporation reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • National Planning Corporation sold 63,100 Intercept Pharmaceuticals, Inc. shares in Q4 2017, an estimated $3.66M.
  • National Planning Corporation first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 12 quarters.
  • National Planning Corporation's Intercept Pharmaceuticals, Inc. position peaked at $8.67M in Q2 2016.
  • 168 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2017.

Based on National Planning Corporation's 13F filing for Q4 2017, filed 14 Feb 2018.